Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
It helps manage blood sugar levels in individuals with type 2 diabetes mellitus
No evidence of cumulative worsening emerged in the Retatrutide trials
Combined with semaglutide (CagriSema), it achieved 15.6% weight loss in a phase 2 trial (2022) over 20 weeks, with phase 3 trials underway
However, it remains unclear whether changes in EAT thicknessand potentially its compositionmerely reflect a general reduction in systemic adipose tissue, and thus simply mirror overall body weight loss in patients treated with GLP-1 receptor agonists, or whether these drugs may induce more specific modifications in EAT that are independent of body weight changes
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
